^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Large B Cell Lymphoma

    26d
    CD20-Negative Primary Intestinal Diffuse Large B-cell Lymphoma With TP53 Mutation in Poorly Controlled Celiac Disease: A Diagnostic Challenge. (PubMed, Cureus)
    The final diagnosis was CD20-negative primary intestinal large B-cell lymphoma with a TP53 mutation arising in the context of poorly controlled CD, a combination that, to the best of our knowledge, has not been previously reported in the literature. This case highlights the diagnostic challenges posed by intestinal lymphomas associated with CD and emphasizes the importance of integrating histopathological, immunophenotypic, and molecular findings to achieve an accurate diagnosis and provide prognostic assessment.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • SDC1 (Syndecan 1) • CD79A (CD79a Molecule) • IRF4 (Interferon regulatory factor 4) • ITGAE (Integrin Subunit Alpha E) • CD2 (CD2 Molecule)
    |
    TP53 mutation • CD20 negative
    26d
    Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas (clinicaltrials.gov)
    P1, N=14, Recruiting, Abramson Cancer Center at Penn Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    26d
    PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma. (PubMed, Leukemia)
    Consistent with these findings, transcriptomic analyses in PMBCL cohorts linked PDCD1LG2 expression to B-cell identity and signaling modules, whereas CD274 expression aligned with interferon-responsive immune programs. Together, these results support a model in which PD-L1 and PD-L2 associate with distinct immune and lineage-associated states in PMBCL and provide a framework for exploring biologically informed stratification strategies in this disease.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    PD-L1 expression
    26d
    Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients (clinicaltrials.gov)
    P1/2, N=91, Recruiting, Curocell Inc. | Trial completion date: Feb 2028 --> Sep 2030 | Trial primary completion date: May 2023 --> Aug 2030
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • Rimqarto (anbalcabtagene autoleucel)
    27d
    Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Nathan Denlinger
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV
    27d
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=16, Completed, Acepodia Biotech, Inc. | Active, not recruiting --> Completed | N=42 --> 16 | Trial completion date: Sep 2027 --> Mar 2026 | Trial primary completion date: Jul 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    27d
    Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Minimal residual disease
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Foresight CLARITY™
    |
    Breyanzi (lisocabtagene maraleucel)
    28d
    ARCHED: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=330, Recruiting, Universitt des Saarlandes | Trial primary completion date: Apr 2028 --> Feb 2029
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
    |
    Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisolone
    28d
    The Impact of the BCR Phenotype of Large B-cell Lymphoma on Ibrutinib Sensitivity. (PubMed, Anticancer Res)
    This premilinary in vitro data suggest a trend toward ibrutinib resistance in Oxphos-type cell lines. More research is warranted both in preclinical models as well as in clinical datasets.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Imbruvica (ibrutinib) • everolimus • Zydelig (idelalisib)
    1m
    GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Chinese PLA General Hospital
    New P1 trial
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    1m
    SOUNDTRACK-B: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL (clinicaltrials.gov)
    P2, N=270, Recruiting, AstraZeneca | Trial completion date: Jun 2029 --> Oct 2032 | Trial primary completion date: Mar 2027 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    surovatamig (AZD0486)
    1m
    A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma. (PubMed, Blood Cancer Discov)
    Here, we describe X-LYMPH (Xenografts of Lymphoma), a publicly available and molecularly annotated PDX repository that captures the heterogeneity of LBCL. X-LYMPH includes models of CAR T-cell resistance, providing a shared foundation for mechanistic research and therapeutic development for lymphomas.
    Journal
    |
    CD19 (CD19 Molecule)